HLA class II transgenic mice develop a safe and long lasting immune response against StreptInCor, an anti-group A streptococcus vaccine candidate

Vaccine

Volumn 29, Issue 46, 2011, Pages 8250-8256

  Guerino, Milton T ^a   Postol, Edilberto ^a   Demarchi, Lea M F ^a   Martins, Carlo O ^a   Mundel, Luiz R ^a   Kalil, Jorge ^a   Guilherme, Luiza ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Histopathology; HLA class ii transgenic mice; Humoral immune response; S. pyogenes; Vaccine

Indexed keywords

ALUMINUM HYDROXIDE; EPITOPE; HLA ANTIGEN CLASS 2; STREPTINCOR EPITOPE; STREPTOCOCCUS VACCINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG SAFETY; HISTOLOGY; HUMORAL IMMUNITY; IMMUNIZATION; IMMUNOGENICITY; IMMUNOLOGICAL MONITORING; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ADJUVANTS, IMMUNOLOGIC; ALUM COMPOUNDS; ANIMAL STRUCTURES; ANIMALS; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; BACTERIAL OUTER MEMBRANE PROTEINS; CARRIER PROTEINS; EPITOPES; FEMALE; HISTOCOMPATIBILITY ANTIGENS CLASS II; HISTOCYTOCHEMISTRY; HUMANS; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; MALE; MICE; MICE, TRANSGENIC; MICROSCOPY; STREPTOCOCCAL VACCINES; STREPTOCOCCUS PYOGENES;

EID: 80053934604     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.08.113     Document Type: Article

References (42)

1. Carapetis J.R., Steer A.C., Mulholland E.K., Weber M. The global burden of group A streptococcal diseases. Lancet Infect Dis 2005, 5(November (11)):685-694.
2. Cardiologia SBd. Brazilian guidelines for the diagnosis, treatment and prevention of rheumatic fever. Arq Bras Cardiol 2009, 93(September (3 Suppl 4)):3-18.
3. Fischetti V.A. Streptococcal M protein. Sci Am 1991, 264(June (6)):58-65.
4. Guilherme L., Kalil J., Cunningham M. Molecular mimicry in the autoimmune pathogenesis of rheumatic heart disease. Autoimmunity 2006, 39(February (1)):31-39.
5. Martins T.B., Hoffman J.L., Augustine N.H., Phansalkar A.R., Fischetti V.A., Zabriskie J.B., et al. Comprehensive analysis of antibody responses to streptococcal and tissue antigens in patients with acute rheumatic fever. Int Immunol 2008, 20(March (3)):445-452.
6. Kraus W., Ohyama K., Snyder D.S., Beachey E.H. Autoimmune sequence of streptococcal M protein shared with the intermediate filament protein, vimentin. J Exp Med 1989, 169(February (2)):481-492.
7. Kraus W., Seyer J.M., Beachey E.H. Vimentin-cross-reactive epitope of type 12 streptococcal M protein. Infect Immun 1989, 57(August (8)):2457-2461.
8. Sargent S.J., Beachey E.H., Corbett C.E., Dale J.B. Sequence of protective epitopes of streptococcal M proteins shared with cardiac sarcolemmal membranes. J Immunol 1987, 139(August (4)):1285-1290.
9. Jones K.F., Khan S.A., Erickson B.W., Hollingshead S.K., Scott J.R., Fischetti V.A. Immunochemical localization and amino acid sequences of crossreactive epitopes within the group A streptococcal M6 protein. J Exp Med 1986, 164(October (4)):1226-1238.
10. Dale J.B., Beachey E.H. Sequence of myosin-crossreactive epitopes of streptococcal M protein. J Exp Med 1986, 164(November (5)):1785-1790.
11. Kaplan M.H. Immunologic relationship of group A streptococcal strains and human heart tissue. Possible significance for the pathogenesis of rheumatic fever. Am Heart J 1963, 65(March):426-427.
12. Guilherme L., Cury P., Demarchi L.M., Coelho V., Abel L., Lopez A.P., et al. Rheumatic heart disease: proinflammatory cytokines play a role in the progression and maintenance of valvular lesions. Am J Pathol 2004, 165(November (5)):1583-1591.
13. Cunningham M.W. Pathogenesis of group A streptococcal infections. Clin Microbiol Rev 2000, 13(July (3)):470-511.
14. Guilherme L., Faé K.C., Oshiro S.E., Tanaka A.C., Pomerantzeff P.M., Kalil J. T cell response in rheumatic fever: crossreactivity between streptococcal M protein peptides and heart tissue proteins. Curr Protein Pept Sci 2007, 8(February (1)):39-44.
15. Guilherme L., Köhler K.F., Kalil J. Rheumatic heart disease: mediation by complex immune events. Adv Clin Chem 2011, 53:31-50.
16. Shulman S.T., Tanz R.R., Dale J.B., Beall B., Kabat W., Kabat K., et al. Seven-year surveillance of north american pediatric group a streptococcal pharyngitis isolates. Clin Infect Dis 2009, 49(July (1)):78-84.
17. Kotloff K.L., Dale J.B. Progress in group A streptococcal vaccine development. Pediatr Infect Dis J 2004, 23(August (8)):765-766.
18. Kotloff K.L., Corretti M., Palmer K., Campbell J.D., Reddish M.A., Hu M.C., et al. Safety and immunogenicity of a recombinant multivalent group a streptococcal vaccine in healthy adults: phase 1 trial. JAMA 2004, 292(August (6)):709-715.
19. Hu M.C., Walls M.A., Stroop S.D., Reddish M.A., Beall B., Dale J.B. Immunogenicity of a 26-valent group A streptococcal vaccine. Infect Immun 2002, 70(April (4)):2171-2177.
20. Olive C., Schulze K., Sun H.K., Ebensen T., Horváth A., Toth I., et al. Enhanced protection against Streptococcus pyogenes infection by intranasal vaccination with a dual antigen component M protein/SfbI lipid core peptide vaccine formulation. Vaccine 2007, 25(February (10)):1789-1797.
21. Guilherme L., Faé K.C., Higa F., Chaves L., Oshiro S.E., Freschi de Barros S., et al. Towards a vaccine against rheumatic fever. Clin Dev Immunol 2006, 13(June-December (2-4)):125-132.
22. Guilherme L., Alba M.P., Ferreira F.M., Oshiro S.E., Higa F., Patarroyo M.E., et al. Anti-group A streptococcal vaccine epitope: structure, stability, and its ability to interact with HLA class II molecules. J Biol Chem 2011, 286(March (9)):6989-6998.
23. Madsen L., Labrecque N., Engberg J., Dierich A., Svejgaard A., Benoist C., et al. Mice lacking all conventional MHC class II genes. Proc Natl Acad Sci USA 1999, 96(August (18)):10338-10343.
24. Pan S., Trejo T., Hansen J., Smart M., David C.S. HLA-DR4 (DRB1*0401) transgenic mice expressing an altered CD4-binding site: specificity and magnitude of DR4-restricted T cell response. J Immunol 1998, 161(September (6)):2925-2929.
25. Gonzalez-Gay M.A., Zanelli E., Khare S.D., Krco C.J., Zhou P., Inoko H., et al. Human leukocyte antigen-DRB1*1502 (DR2Dw12) transgene reduces incidence and severity of arthritis in mice. Hum Immunol 1996, 50(September (1)):54-60.
26. Bradley D.S., Nabozny G.H., Cheng S., Zhou P., Griffiths M.M., Luthra H.S., et al. HLA-DQB1 polymorphism determines incidence, onset, and severity of collagen-induced arthritis in transgenic mice, Implications in human rheumatoid arthritis. J Clin Invest 1997, 100(November (9)):2227-2234.
27. Nabozny G.H., Baisch J.M., Cheng S., Cosgrove D., Griffiths M.M., Luthra H.S., et al. HLA-DQ8 transgenic mice are highly susceptible to collagen-induced arthritis: a novel model for human polyarthritis. J Exp Med 1996, 183(January (1)):27-37.
28. Chapoval S.P., Neeno T., Krco C.J., Marietta E.V., Harders J., David C.S. HLA-DQ6 and HLA-DQ8 transgenic mice respond to ragweed allergens and recognize a distinct set of epitopes on short and giant ragweed group 5 antigens. J Immunol 1998, 161(August (4)):2032-2037.
29. Laemmli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970, 227(August (5259)):680-685.
30. Towbin H., Staehelin T., Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci USA 1979, 76(September (9)):4350-4354.
31. Singh M., O'Hagan D. Advances in vaccine adjuvants. Nat Biotechnol 1999, 17(November (11)):1075-1081.
32. Ribeiro S.P., Rosa D.S., Fonseca S.G., Mairena E.C., Postól E., Oliveira S.C., et al. A vaccine encoding conserved promiscuous HIV CD4 epitopes induces broad T cell responses in mice transgenic to multiple common HLA class II molecules. PLoS One 2010, 5(6):e11072.
33. Galvin J.E., Hemric M.E., Kosanke S.D., Factor S.M., Quinn A., Cunningham M.W. Induction of myocarditis and valvulitis in lewis rats by different epitopes of cardiac myosin and its implications in rheumatic carditis. Am J Pathol 2002, 160(January (1)):297-306.
34. Faé K.C., da Silva D.D., Oshiro S.E., Tanaka A.C., Pomerantzeff P.M., Douay C., et al. Mimicry in recognition of cardiac myosin peptides by heart-intralesional T cell clones from rheumatic heart disease. J Immunol 2006, 176(May (9)):5662-5670.
35. Lymbury R.S., Olive C., Powell K.A., Good M.F., Hirst R.G., LaBrooy J.T., et al. Induction of autoimmune valvulitis in Lewis rats following immunization with peptides from the conserved region of group A streptococcal M protein. J Autoimmun 2003, 20(May (3)):211-217.
36. Gorton D., Govan B., Olive C., Ketheesan N. B- and T-cell responses in group a streptococcus M-protein- or Peptide-induced experimental carditis. Infect Immun 2009, 77(May (5)):2177-2183.
37. Gorton D., Blyth S., Gorton J.G., Govan B., Ketheesan N. An alternative technique for the induction of autoimmune valvulitis in a rat model of rheumatic heart disease. J Immunol Methods 2010, 355(April (1-2)):80-85.
38. Cunningham M.W. T cell mimicry in inflammatory heart disease. Mol Immunol 2004, 40(February (14-15)):1121-1127.
39. Ellis N.M., Li Y., Hildebrand W., Fischetti V.A., Cunningham M.W. T cell mimicry and epitope specificity of cross-reactive T cell clones from rheumatic heart disease. J Immunol 2005, 175(October (8)):5448-5456.
40. Goodson H.V., Spudich J.A. Molecular evolution of the myosin family: Relationships derived from comparisons of amino acid sequences. Proc Natl Acad Sci USA 1993, January (90):659-663.
41. Alpert N.R., Brosseau C., Federico A., Krenz M., Robbins J., Warshaw D.M. Molecular mechanics of mouse cardiac myosin isoforms. Am J Physiol Heart Circ Physiol 2002, 283(June):H1446-H1454.
42. Foth B.J., Goedecke M.C., Soldati D. New insights into myosin evolution and classification. Proc Natl Acad Sci USA 2006, 103(March (10)):3681-3686.